Financial plays

Nestlé buys Louisiana depression food firm

Nestlé buys Louisiana depression food firm

By Shane STARLING

Nestlé has bought its second brain health-focused medical foods start-up in eight months after snaffling Red River Pharma-owned Pamlab which makes high-dose vitamin supplements targeting depression, diabetes and Alzheimer’s.

How high can high-end omega-3 go?

Special edition: Omega-3 (Editor's blog)

How high can high-end omega-3 go?

By Shane STARLING

Just got off the phone to Ola Snove, the new(ish) CEO of Aker part-owned Norwegian omega-3 specialist Epax. Wanted to know his view on high-end omega-3 prospects that have attracted BASF and DSM to the sector. His word: “Stellar”.

Probi 2012 sales up 6%, but ProViva royalties set for dive

Probi 2012 sales up 6%, but ProViva royalties set for dive

By Shane Starling

The European probiotic sector is bracing itself for tough times ahead in the wake of December’s  EU health claim ban for the sector, but the effects are yet to be felt at Swedish supplier Probi which notched 6% sales growth in 2012.

Chobani’s global ambitions: Too much, too young?

EDITOR'S OPINION: DEAR DAIRY....

Chobani’s global ambitions: Too much, too young?

By Mark Astley

At just seven years old, Chobani is a poster boy in the eyes of some, a market-devouring monster in the eyes of others. The New York-based Greek yogurt giant’s expansion plans in North America, Europe and Australasia are ambitious. But is it taking on...

The year ahead: 2013 European nutra futures

The year ahead: 2013 European nutra futures

By Shane STARLING

The economic crisis has hit the EU hard, and coupled with a severe health and nutrition claim clamp down, the past years have been challenging for the European nutra industry.

DSM broadens its range (again) with oat beta-glucan

DSM buys Swedish oat beta-glucan brand

By Shane Starling

A day after confirming the €500m acquisition of New York-based blends specialist Fortitech, Royal DSM has concluded the year by buying beta-glucan brand Oatwell from Swedish Oat Fiber (SOF).

Evolva will reduce the cost of its new yeast-derived resveratrol, it says

Evolva pays €550,000 for Fluxome resveratrol business

By Shane Starling

Swiss biotech firm Evolva has bought failing Fluxome’s, yeast-derived resveratrol business for about €550,000 in cash and shares, but says it has no interest in the remaining omega-3 business being sold by sealed auction.

Follow us

Featured Events

View more

Products

View more

Webinars